Clinical Trial Approval in Australia

INVESTIGATIONAL NEW DRUG ALMB-0168GRANTED CLINICAL TRIAL APPROVAL IN AUSTRALIA  CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) Hong Kong, 24 February 2020 The board of directors (the...

Submission of Clinical Trial Application in Australia

SUBMISSION OF CLINICAL TRIAL APPLICATION FOR INVESTIGATIONAL FIRST-IN-CLASS NEW DRUG ALMB-0168 IN AUSTRALIA  CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) Hong Kong 27 November 2019 The...

ALMB-0168 Granted Rare Pediatric Disease Designation

FIRST-IN-CLASS PRODUCT CANDIDATE ALMB-0168GRANTED RARE PEDIATRIC DISEASE DESIGNATION BY THE U.S. FDA  CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) Hong Kong, 18 October 2019 The board of...

FIRST-IN-CLASS PRODUCT CANDIDATE ALMB-0168

First-in-Class Product Candidate ALMB-0168Granted Orphan-Drug Designation by the U.S. FDA  CSPC Pharmaceutical Group Limited 石 藥 集 團 有 限 公 司 (Incorporated in Hong Kong under the Companies Ordinance)(Stock Code: 1093) Hong Kong, 23 September 2019 The board of directors...